Viral warts – manifestations of cutaneous infection by human papilloma virus – can be a significant physical and emotional burden for patients when common treatments fail, particularly for individuals who are immunocompromised or with multiple lesions. Cidofovir, an antiviral agent typically used for the treatment of cytomegalovirus infection, has emerged as an alternative treatment option for viral warts when administered topically or intralesionally. In this review, we highlight the scientific rationale, published evidence, and practical clinical uses of intralesional cidofovir for the management of cutaneous warts as well as ongoing questions requiring further research and exploration of this emerging therapy for refractory verrucae.

No abstract

No abstract

No abstract

No abstract

This survey study assesses dermatology patient experiences with viewing online medical records and seeks to identify areas for improvement

No abstract

We assessed dermatologists’ knowledge and comfort levels in prescribing various medications. Knowledge gaps in the management of cyclophosphamide, opioid pain controllers, intravenous immunoglobulin, and newer-generation biologics were observed. Dermatologists expressed greater concern about prescribing medications that are broadly immunosuppressive with severe side effects such as cyclophosphamide and rituximab.